WINTON GROUP Ltd Acquires Shares of 106,852 Trevi Therapeutics, Inc. $TRVI

WINTON GROUP Ltd bought a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 106,852 shares of the company’s stock, valued at approximately $1,993,000. WINTON GROUP Ltd owned about 0.07% of Trevi Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of TRVI. BlackRock Inc. purchased a new stake in shares of Trevi Therapeutics during the second quarter valued at approximately $208,041,000. Rubric Capital Management LP grew its stake in Trevi Therapeutics by 88.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock valued at $46,669,000 after purchasing an additional 3,993,325 shares during the period. Vanguard Group Inc. increased its position in shares of Trevi Therapeutics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 5,826,986 shares of the company’s stock valued at $53,317,000 after purchasing an additional 510,295 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Trevi Therapeutics by 9.5% during the 2nd quarter. Wellington Management Group LLP now owns 5,684,592 shares of the company’s stock valued at $106,018,000 after purchasing an additional 495,504 shares during the last quarter. Finally, Viking Global Investors LP raised its stake in shares of Trevi Therapeutics by 232.4% during the 3rd quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock worth $46,929,000 after purchasing an additional 3,585,875 shares during the period. 95.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Friday, July 17th. BMO Capital Markets assumed coverage on shares of Trevi Therapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $36.00 target price on the stock. B. Riley Financial increased their target price on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, July 20th. JonesTrading raised their price target on shares of Trevi Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Finally, Oppenheimer lifted their price target on shares of Trevi Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $27.08.

Trevi Therapeutics Stock Down 0.1%

NASDAQ TRVI opened at $15.90 on Friday. The company has a market cap of $2.27 billion, a PE ratio of -46.76 and a beta of 1.04. Trevi Therapeutics, Inc. has a 52 week low of $7.64 and a 52 week high of $20.22. The firm’s 50-day simple moving average is $17.80 and its two-hundred day simple moving average is $15.19.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). As a group, equities research analysts anticipate that Trevi Therapeutics, Inc. will post -0.48 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic cough and other conditions involving dysregulated sensory nerve activity. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine designed to reduce chronic cough through activity at opioid receptors.

Trevi is studying Haduvio for chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, as well as refractory chronic cough, a condition in which coughing persists despite treatment of underlying causes.